Skip to main content
Fig. 1 | Reproductive Health

Fig. 1

From: Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial

Fig. 1

Trial flow diagram showing the participants flow and numbers from enrollment, allocation, follow up and analysis between January 2014 and February 2015. Two hundred and forty seven HSV-2 positive women were eligible for enrollment. Forty-seven women were excluded. One participant had active genital herpes and needed a therapeutic course of acyclovir. One woman had diabetes and HIV and had large drug load. Forty-five participants came after 28 weeks or after sample size was realised. We thus had the 200 participants who were eligible and randomised half of them in the acyclovir arm and the other half in the placebo arm. We followed up all participants to 36 weeks or up to membrane rupture, if it occurred before that and the primary outcome was assessed then

Back to article page

Reproductive Health

ISSN: 1742-4755